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AbstrACt
Introduction Chronic headaches are poorly diagnosed 
and managed and can be exacerbated by medication 
overuse. There is insufficient evidence on the non- 
pharmacological approaches to helping people living 
with chronic headaches.
Methods and analysis Chronic Headache Education 
and Self- management Study is a pragmatic randomised 
controlled trial to test the effectiveness and cost- 
effectiveness of a self- management education support 
programme on top of usual care for patients with 
chronic headaches against a control of usual care and 
relaxation. The intervention is a 2- day group course 
based on education, personal reflection and a cognitive 
behavioural approach, plus a nurse- led one- to- one 
consultation and follow- up over 8 weeks. We aim 
to recruit 689 participants (356 to the intervention 
arm and 333 to the control) from primary care and 
self- referral in London and the Midlands. The trial is 
powered to show a difference of 2.0 points on the 
Headache Impact Test, a patient- reported outcome 
measure at 12 months post randomisation. Secondary 
outcomes include health related quality of life, self- 
efficacy, social activation and engagement, anxiety 
and depression and healthcare utilisation. Outcomes 
are being measured at 4, 8 and 12 months. Cost- 
effectiveness will be expressed in terms of incremental 
cost per quality- adjusted life year gained.
Ethics and dissemination This trial will provide 
data on effectiveness and cost- effectiveness of a 
self- management support programme for chronic 
headaches. The results will inform commissioning of 
services and clinical practice. North West – Greater 
Manchester East Research Ethics Committee have 
approved the trial. The current protocol version is 3.6 
date 7 March 2019.
trial registration number ISRCTN79708100.
IntroduCtIon
Headache disorders are a major cause of pain 
and disability.1 A definition of a chronic head-
ache disorder used in epidemiological studies 
is that the person has headache for 15 or 
more days per month for at least 3 months.2–4 
Other authors prefer the term chronic daily 
headache, but this is less clearly defined.5 
Chronic headache disorders mainly affect the 
young adult population, many of whom have 
both work and family commitments.6 The 
most common chronic headache disorders 
are chronic tension type headache, chronic 
strengths and limitations of this study
 ► This trial presents a high- quality randomised con-
trolled trial designed to determine the effectiveness 
and cost- effectiveness of a group self- management 
support programme for adults with chronic 
headaches.
 ► The intervention underpinning the trial is a complex 
intervention that has been designed using the best 
available evidence and theory. The full details of the 
intervention development and design have been 
peer reviewed and published.
 ► A separate mixed- methods process evaluation is 
running alongside the trial and will explore fidelity 
of the intervention and implementation. A detailed 
process evaluation protocol has been peer reviewed 
and published.
 ► The success of the trial will be dependent on the 
ability to deliver this complex group intervention, en-
sure fidelity and subsequently obtain follow- up data 
in this population.
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migraine and medication overuse headaches (MOHs).1 
Tension type headache and migraine are primary head-
aches. Medication overuse is a secondary headache that 
can develop in people with frequent acute headaches 
who take analgesics or specific antimigraine compounds 
(eg, triptans) for ≥10 days per month.
Around 2%–4% of the global population experience 
chronic daily headaches.7 Between a quarter and half of 
those affected also have MOH, which has a prevalence 
of 1%.8–10 Many people with chronic headache have 
undiagnosed chronic migraine.11 More appropriate 
use of pharmacological treatment has the potential to 
improve outcomes for people living with chronic head-
ache disorders. This might mean introducing migraine 
prophylactic drugs or using fewer analgesics/triptans. 
Depression, anxiety, poor sleep, stress and poor self- 
efficacy for managing headaches are prognostic markers 
for a poor outcome in chronic headache disorders.12 
Limited qualitative data indicate that chronic headache 
disorders can directly and indirectly drive behaviour: that 
people live with the ‘spectre of headache’ (an array of 
concerns people with chronic headaches have to take 
into account when forward planning) and that head-
aches lead to strained relationships.13 For people living 
with chronic migraine or chronic tension type headache, 
non- pharmacological self- management approaches may 
improve headache- related symptoms while not affecting 
headache frequency.14 Group interventions using a cogni-
tive behavioural approach, mindfulness and educational 
components may be more effective than alternative 
interventions.14
Supportive self- management approaches are well estab-
lished in the management of several chronic painful 
disorders, but this is not the case for chronic headache 
disorders.15–17 The National Institute for Health and Care 
Excellence (NICE) guidance in England, for example, 
only makes one positive recommendation for a non- 
pharmacological treatment for people living with chronic 
migraine or chronic tension type headache: to consider a 
course of acupuncture for people with chronic migraine 
or chronic tension type headache.18
We describe here the protocol for a randomised 
controlled trial (RCT) to estimate the effectiveness and 
cost- effectiveness of a group self- management support 
programme for adults with chronic headaches arising 
from migraine or tension type headache, with or without 
medication overuse. The Chronic Headache Educa-
tion and Self- management Study (CHESS) intervention 
consists of a group education and self- management 
support programme plus a tailored one- to- one headache 
consultation exploring medication optimisation, lifestyle 
factors and goals. This active arm of the trial is being 
compared with usual care plus a relaxation programme.
MEthods And AnAlysIs
The methods section is structured in accordance with 
the SPIRIT 2013 recommendations.19 Here we provide 
an overview of the trial plus a brief description of the 
proposed health economic evaluation, process evaluation 
and patient and public involvement (PPI).
The primary objective is to estimate the clinical 
and cost- effectiveness of a group education and self- 
management programme for people living with chronic 
headache recruited from primary care when compared 
with a general practitioner (GP) care plus relaxation 
control group.
Participants, interventions and outcomes
Study setting
Primary care settings in two localities: London and the 
Midlands.
Eligibility criteria
The population of interest are adults living with chronic 
migraine or chronic tension type headache, with or 
without medication overuse. Part of the challenge in 
interpreting the findings of research in people living 
with chronic headaches is the often poor reporting of 
participants’ phenotypic characteristics, meaning it is not 
possible to draw conclusions for specific chronic head-
ache types.13 20 For this trial, it is important that we are able 
to define our participants’ headache type, or types, accu-
rately and exclude those with non- eligible headache types. 
We, therefore, developed and validated a logic model for 
use in a telephone interview by a nurse (non- headache 
expert) that would allow us to identify and classify people 
meeting our entry criteria while also excluding people 
with secondary headaches, other than medication overuse 
and other causes of primary headaches (table 1).21
Pregnancy is not an exclusion criterion. However, any 
pregnant women randomised to the active interven-
tion will be advised to speak to their GP with regards to 
medication, and the CHESS intervention nurses will not 
discuss this with them during the consultation for safety 
reasons.
Our previous experience is that the challenges of 
running non- English language group interventions for 
chronic painful disorders are too great to do success-
fully within an RCT.22 Furthermore, the main outcomes 
are not validated in those languages other than English, 
which are relevant to a UK context. For these reasons, we 
are excluding people who are not fluent in written and 
spoken English.
In this pragmatic trial, our entry criteria reflect the 
point in the care pathway where our intervention will 
be offered. Specifically, general practitioners will refer 
people they identify with chronic headaches into the 
service. Thus, there is not the pre randomisation run- in 
one might expect in a more explanatory drug trial, and 
we base assessment of the presence of chronic headache 
on a single telephone assessment and include a mixture 
of headache types.
Interventions
The intervention consists of a group education and self- 
management programme, an 8- week headache paper 
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Able and willing to comply with the study procedures and 
provide written informed consent.
2. Aged ≥18 years (no upper limit).
3. Living with chronic headache; defined as headache on 15 
or more days per month for at least the preceding 3 months.
4. The nurse telephone classification interview confirms 
headache type to be chronic migraine, or chronic tension 
type headache, with or without medication overuse 
headache.
5. Fluent in written and spoken English.
1. Unable to attend the group sessions.
2. No access to a telephone (for classification interview).
3. Has an underlying serious psychological disorder with 
ongoing symptoms that preclude or significantly interfere 
with participation in the group intervention.
4. Previous entry or randomisation in the present trial.
5. Currently participating in another clinical trial of headache 
treatments or unregistered medicinal product or less than 
90 days have passed since completing participation in such 
a trial.
diary, a one- to- one nurse- led consultation and follow- up 
telephone calls, where necessary, for up to 8 weeks. We 
have described its development in detail elsewhere.23 We 
summarise it briefly here.
The programme is run over 2 days in a 2- week period 
for around 10 participants per group (target 6–12 partic-
ipants) and is facilitated by two intervention trained 
healthcare professionals, at least one of whom is a nurse 
(the second facilitator could be a nurse or other regis-
tered allied health professional such as psychologist, phys-
iotherapist, chiropractor and occupational therapist). We 
originally planned to run sessions using a nurse and a lay 
facilitator living with chronic headaches. However, in our 
feasibility study, we found it difficult to recruit people 
living with chronic headaches to act as facilitators and 
of those that were recruited several found it difficult to 
commit to facilitation of courses because of the unpre-
dictability of their condition. The intervention builds 
on a previously developed and tested educational and 
cognitive behavioural self- management intervention for 
people with chronic musculoskeletal pain.24
The aim of the course is to encourage and enable 
those with chronic headaches to recognise unhelpful 
thought patterns and behaviours that contribute to their 
headache burden and to do something about them. The 
course provides participants with an overall toolbox of 
strategies that could help in the management of their 
headaches. These strategies include psychological tech-
niques to change perceptions and feelings about living 
with chronic headaches as well as more practical strate-
gies around lifestyle factors and medication. The group 
intervention is delivered using a range of methods 
including: group discussions, ideas generation, sharing 
narratives and experiences, problem solving, role play 
and taster activity sessions. The programme includes a 
range of behaviour change techniques including: barrier 
identification, general encouragement, instruction from 
the group facilitators, provision of feedback and allowing 
opportunities for social comparison in the group. We 
also include an educational video (available on disc and 
online) following feedback from our PPI group on the 
importance of having something to show family and 
friends about their ‘invisible’ disorder.
The sessions take place on weekdays and, where 
possible, during school hours to accommodate those 
with child care responsibilities. Sessions are held in easily 
accessible community venues and GP practices.
Participants in the intervention arm are asked to 
complete a paper headache diary for a period of up to 
8 weeks prior to the 2- day programme. A one- to- one, indi-
vidually tailored nurse- led consultation follows the 2- day 
programme. During this session, the nurse classifies the 
participant’s headache type, discuss medication and life-
style factors and explore participants’ goals. This discus-
sion is backed up by written information (for patient and 
GP), consistent with NICE guidance, to support shared 
informed decision making between the patient and 
their GP, about medication choices.25 All participants 
will be offered telephone follow- up for up to 8 weeks. 
The frequency of these follow- up calls will be individu-
ally negotiated and agreed with participants during the 
one- to- one consultation. Full details of the intervention 
content have been published elsewhere.23
Control intervention
Previous studies of this nature have reported that a 
usual care control arm was not an incentive to join the 
study.15 We know from experience that patients enjoy the 
relaxation part of pain self- management programmes.17 
Therefore, as an incentive to participate, the control 
group receive standard usual care plus a relaxation CD 
and instructions for use over the duration of the study, up 
until final follow- up at 12 months. Participants are free to 
continue using the relaxation CD thereafter should they 
wish.
As all participants in the trial have a headache classifi-
cation interview prior to randomisation, we feed back the 
results of that classification interview to control partici-
pants, and their GPs, together with advice on headache 
management. In this way, we ensure all participants 
receive best usual care.
The relaxation CD or downloadable MPG file (from 
the CHESS website) consists of a 17 min relaxation 
audio script that starts by focusing on the breath before 
talking the participant through progressive relaxation of 
muscles. The participants in the control group choose 
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when, where and how often they do the relaxation but 
are advised to try it two to three times a week or as often 
as they feel appropriate over the course of the study.
Facilitator recruitment and training
All group sessions have two facilitators: one of whom must 
be a registered nurse, while the other facilitator is any 
allied healthcare professional, registered with a regula-
tory body, with an interest in this patient population and 
condition. Facilitators were recruited via advertisements 
in allied healthcare profession organisations and trained 
over a 2- day period to deliver the self- management inter-
vention. Nurses received a further day of training to 
cover the one- to- one consultations. The training course 
covers the content of the intervention, facilitation skills, 
managing groups and trial procedures. Those under-
going the training were assessed using a learning assess-
ment form at the end of the training course to check their 
knowledge and understanding. Those evaluated to be 
competent were asked to deliver the intervention. Those 
who either struggled with some elements of the content 
or expressed any concerns about delivering the interven-
tion were provided with additional one to one support by 
the trainers.
Intervention quality assessment
Quality assurance of the intervention is important to 
ensure that the trial intervention is delivered consistently 
and in accordance with the trial protocol and manuals. As 
part of the intervention development, we have produced 
two very detailed manuals: the first that covers the 2 days 
of group sessions and the second that details the process 
for the one to one consultations. All facilitators have 
been appropriately trained on the delivery of the inter-
vention in accordance with the manuals. They have been 
instructed to use the manuals to guide them through 
delivery of the intervention.
To assure the quality of the course delivery, we will aim 
to observe each facilitator. We will observe each facilitator 
early in their facilitation to allow any difficulties or chal-
lenges to be addressed. Subsequently, they will be observed 
midway through. Observations will be by session, and the 
number of sessions observed will depend on the ability of 
the observer to capture the required information.
The observations will be conducted by members of the 
CHESS team who have knowledge of the intervention 
and its delivery. Observers will complete an observation 
form that will address facilitator skills and adherence to 
content delivery. Feedback will be provided on the day 
where possible. If this is not possible, the observer will 
arrange to contact the facilitator by phone. The study 
team will discuss any difficulties with the facilitator to 
minimise impact on the rest of the course and to help 
with the delivery of future courses. For any facilitators 
struggling, the central research team will monitor their 
personal reflections for the remaining duration of the 
course and follow- up with phone calls if required.
Outcome measures: primary outcome measure; headache-related 
quality of life
Our primary outcomes is headache- related quality of 
life assessed at the primary endpoint, 12 months after 
randomisation. For sample size determination, we have 
specified the Headache Impact Test (HIT-6), a six- item 
patient- reported outcome measure (PROM), as our 
measure of the primary outcome.26 The HIT-6 provides a 
short overall assessment of headache impact – with items 
assessing fatigue, pain, social functioning, emotional 
well- being and cognition. Prior to selecting our outcome 
measures, we did a systematic review of PROMs for 
headaches.27 Only for the HIT-6 did we find acceptable 
evidence supporting its use for our target population who 
may not have been given a headache diagnosis prior to 
study entry.
Another measure, shortlisted in the review, was the 
14- item Migraine- Specific Quality of Life Questionnaire 
(MSQ v2.1) assesses the role restrictions, limitations 
and emotional impact of migraine.27 The MSQv2.1 has 
acceptable evidence of psychometric properties following 
completion in a migraine population.27–30
To inform our selection of outcome measures, we 
undertook interviews (n=14) with people with chronic 
headache. Our participants described greater perceived 
relevance of the MSQ (v2.1) compared with the HIT-6. 
With permission from GSK, the copyright holders, we 
modified the MSQ (v2.1), changing the focus from 
‘migraine’ to ‘headache’; the modified measure was 
renamed as the ‘Chronic Headache Quality of Life Ques-
tionnaire’ (CHQLQ v1.0). In our ongoing work, we are 
assessing the performance of this modified instrument. 
In the event its performance is superior to the HIT-6, we 
will consider changing the primary outcome.
Both the HIT-6 and the CHQLQ v1.0 will be collected 
via postal questionnaire at baseline, 4, 8 and 12 months 
post randomisation.
Outcome measures: other secondary outcomes measures
The following secondary outcome measures are being 
collected:
1. Headache days: our main outcome describing head-
aches days will be headaches days in the preceding 
month reported at baseline and follow- up postal ques-
tionnaires. We will also estimate total headaches days 
over the whole study period from patient- reported 
data collected via a smartphone app.
2. Headache impact: we will assess headache impact based 
on their typical duration and severity reported in base-
line and follow- up questionnaires.
3. Composite headache outcome: we will produce a composite 
headache outcome of headache days × severity × du-
ration using data from the smartphone app and ques-
tionnaires.
4. Generic health- related quality of life: we have included two 
standard measures of health- related quality of life—
the (SF-12 V2) Short Form Survery 12 Version 2 and 
(EQ- 5D- 5L) EuroQol five dimension scale.31–33 There 
 o
n
 April 14, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033520 on 12 April 2020. Downloaded from 
5Patel S, et al. BMJ Open 2020;10:e033520. doi:10.1136/bmjopen-2019-033520
Open access
is limited, but acceptable, evidence supporting the use 
of the SF-12 V2 to assess overall quality of life in a head-
ache population.27 There is no such evidence for the 
EQ- 5D- 5L.27 We will, therefore, use EQ- 5D- 5L primari-
ly for our health economic analyses.32
5. Emotional well- being: Hospital Anxiety and Depression 
Scale (HADs) – psychological distress is extremely 
common in people living with chronic pain. HADs has 
been used in many previous studies of chronic pain, 
including the COPERS (Coping with persistent Pain, 
Effectiveness Research into Self- management) study 
where we identified positive effects on both anxiety 
and depression in a chronic pain population.22 34
6. Self- efficacy: Pain Self- Efficacy Questionnaire (PSEQ) 
– self- efficacy is an important mediator for how self- 
management interventions may improve patient out-
comes. It is important, therefore, to measure change 
in self- efficacy as part of understanding the causal 
pathway for any change and informing our process 
evaluation.35 We have previously reviewed measures of 
self- efficacy and concluded that PSEQ is the most ap-
propriate choice for studies of this nature; although all 
current measures have limitations.36
7. Social activity: Social Integration Subscale (SIS) of the Health 
Education Impact Questionnaire (heiQ) – chronic head-
ache can result in a disrupted lifestyle and a reduced 
quality of life both during and between attacks; the im-
pact of chronic headache on an individual’s ability to 
commit to social plans is an important aspect of quality 
of life. Successful treatment should seek to improve 
both overall quality of life, as well as an individual’s 
quality of life during the attack, including their abili-
ty to integrate in society. A well- developed, condition- 
specific measure should seek to capture these distinc-
tions. The five- item SIS is one of eight domains con-
tained within the heiQ, a measure of the impact of pa-
tient education programmes in chronic conditions.37
8. Bodily pain: chronic headache commonly coexists 
with other chronic painful disorders such as low 
back pain.38–41 The CHESS intervention might af-
fect the troublesomeness of other bodily pains. We 
will collect these data using a previously validated 
Troublesomeness Grid.42
At baseline we also collect data on age, gender, ethnic 
group, age at leaving full- time education and current 
work status.
We will collect follow- up data at 4, 8 and 12 months 
after randomisation by postal questionnaire survey. A £5 
high street voucher is enclosed as a token of our appre-
ciation at each initial time point. We will send out two 
postal follow- up reminders. In the event that no response 
is obtained, we will aim to collect our primary clinical 
outcome data by telephone. This includes the HIT-6 and 
EQ- 5D- 5L.
The smartphone data will be collected weekly for 
6 months from initial eligibility and then monthly until 12 
months after randomisation. A paper version of the app 
will be available to those who do not use a smartphone.
If there are missing data (for our key clinical outcomes), 
this will be followed up with the participant who 
completed the form, as soon as possible by a member of 
the team over the phone. We will phone the participant 
and enter the correct information onto the form; this will 
be initialled and dated.
Participant timelines
Figure 1 shows the recruitment flow, and table 2 shows 
the study timelines.
Sample size
For the purposes of our sample size calculation, the 
primary clinical outcome is the difference in mean HIT-6 
score at 12 months post randomisation between the self- 
management group programme and the usual care relax-
ation therapy (control arm). The HIT-6 outcome measure 
is a continuous scale with higher values indicating more 
severe impact on daily life. From our systematic reviews, 
we anticipate a worthwhile difference to be 2.0, that is, 
mean outcome in the control arm is 2.0 units higher than 
for the intervention.27 43 In our feasibility study (n=114), 
the SD of the HIT-6 score at baseline was 6.87.44
Participants are randomised to either the self- 
management group or usual care and relaxation therapy. 
In this design, there may be a clustering effect in the self- 
management group and not in the control arm, which 
needs to be allowed for in the sample size calculation. 
Based on similar trials, we assume that the intraclass 
correlation coefficient is 0.01.22 The anticipated average 
size of the self- management programme is 10.
The minimum sample size required was estimated using 
Moerbeek and Wong’s method to account for grouping 
in one arm.45 To detect a between- group difference of 2.0 
with SD of 6.9 (a standardised mean difference of 0.29) 
and assuming that the ratio of the total variance in the 
self- management group to the relaxation therapy is 1 
at the two- sided 5% significance level and at least 90% 
power, the sample size required is 523 participants (253 
in the relaxation group and 270 in the self- management 
group).
In the feasibility study, the overwhelming majority of 
those recruited, approximately 95%, chronic migraine; 
just 5% had chronic tension type headache. We want 
to be able to draw definite conclusions on the specific 
subgroup of chronic migraine. Therefore, we will base 
our sample size and primary clinical outcome on the 
population with chronic migraine. Therefore, based on 
95% of our sampled population with chronic migraine 
and accounting for a 20% loss to follow- up as above, the 
sample size we would require is 689 with 333 to the relax-
ation arm and 356 to the self- management programme.
In the feasibility study, we recruited around 1/1000 of 
practice population to take part44; we therefore anticipate 
we need to recruit from around 100 general practices 
with a combined list size of around 700 000.
In consultation with the Data Monitoring and Ethics 
Committee (DMEC), we will review the sample size 
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Figure 1 This shows the recruitment flow chart. 
*Genetal practitioner; National Migraine Center; Definite Chronic Migraine; Probable Chronic Migraine; Tension Type He adache; 
Medication Overuse He adache. 
DMC, definite chronic migraine; GP, general practitioner; MOH, medication overuse headache; PCM, probable chronic migraine; 
TTH, tension type headache.
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Table 2 Schedule of enrolment, interventions and assessments
Activity
Pre- enrolment 
to allocation
Randomisation 
to 12 weeks 4 months 8 months
12 
months
Expression of interest ×
Trial information ×
Download app to record headache patterns (weekly for 
6 months and then monthly until the end of follow- up at 
12 months)
× × × × ×
Questionnaire demographic information, HIT-6, 
CHQLQ, headache days, SF12, EQ- 5D- 5L, HADs, 
PSEQ, HeiQ and troublesomeness
×
Consent ×
Headache classification interview ×
Allocation ×
Intervention plus completion of paper headache diary 
for duration of up to 8 weeks before attending group
×
Control ×
HIT-6, CHQLQ, headache days, SF12, EQ- 5D- 5L, 
HADs, PSEQ, HeiQ and troublesomeness
×
Two postal follow- up reminders and phone call for PO 
if needed
×
HIT-6, CHQLQ, headache days, SF12, EQ- 5D- 5L, 
HADs, PSEQ, HeiQ and troublesomeness
×
Two postal follow- up reminders and phone call for PO 
if needed
×
HIT-6, CHQLQ, headache days, SF12, EQ- 5D- 5L, 
HADs, PSEQ, HeiQ and troublesomeness
×
Two postal follow- up reminders and phone call for PO 
if needed
×
CHQLQ, Chronic Headache Quality of Life Questionnaire; EQ- 5D- 5L, EuroQoL; HADs, Hospital Anxiety and Depression Scale; HeiQ, Health 
Education Impact Questionnaire; HIT-6, Headache Impact Test; PO, Primary outcome; PSEQ, Pain Self- Efficacy Questionnaire; SF12, Short 
Form 12- item Health Survey.
around halfway through recruitment to ensure we have 
recruited sufficient participants with chronic migraine 
and revise our estimates using within trial data on the 
variance of our primary outcome at baseline. This review 
will be based on the headache classification and actual 
baseline SD of our sampled population. We might also 
need to recruit some additional participants to ensure 
that the final group sessions at each site are adequately 
populated.
Recruitment
Participants are identified and invited into the study in 
two ways. First, practices run electronic searches on their 
databases to identify people who have consulted with 
headaches or have been prescribed migraine specific 
drugs (eg, triptans and pizotifen) in the preceding 
2 years. Practices then screen the lists for those it would be 
inappropriate to approach (eg, poorly controlled serious 
mental illness, terminal illness or known secondary causes 
of headache such as primary or secondary brain tumours) 
and send approach letters to the remainder.
People can self- refer to the trial. Participating general 
practices, the principal pharmacies used by their patients, 
are supplied with a study poster for display in patient 
areas inviting people to contact the study team if they 
have headaches and are interested in participating. Infor-
mation about the trial is made available on the poster (in 
general practices and pharmacies) and websites (https:// 
warwick. ac. uk/ fac/ med/ research/ ctu/ trials/ other/ 
chess/ and https:// warwick. ac. uk/ fac/ med/ research/ 
ctu/ trials/ chess. People who find about the trial through 
the internet or following media exposure, and can travel 
to sessions, can also self- refer to the trial.
Using both approaches will allow people receiving GP 
treatment for chronic headaches who are not coded in 
the GP system as having headaches, and those who are 
self- medicating their headaches, the opportunity to join 
the study. We anticipate that we will primarily recruit 
people registered with participating practices; however, 
we will not restrict recruitment to those registered with 
participating practices.
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Table 3 Questions completed on the smartphone app
Question Mode of response
On how many of the last 7 days 
have you had a headache?
Insert number of 
headache days
On those days you had a 
headache, on average how long 
did they last?
Insert number of hours
On those days you had a 
headache, on average how 
severe were they?
Scale of 0–10 (with 0 
being no pain and 10 
extremely severe pain)
In addition to these two main recruitment strategies, a 
study press release was submitted in January 2018, which 
was picked up by various media outlets and generated 
further interest in the study from potential participants.
The study coordinating team contact people expressing 
an interest in the study and check that they are eligible, 
explain the study and obtain participant’s verbal consent 
to start completing an electronic headache symptom 
severity, duration and frequency diary (or paper version 
where there is no access to the internet). The electronic 
diary is completed weekly for the first 6 months and subse-
quently monthly until the end of follow- up at 12 months. 
The electronic diary is used to identify any early effects 
of rebound headache in those with MOH. At this time 
participants are sent a baseline questionnaire and consent 
form to return in a freepost envelope.
Following receipt of baseline questionnaire and consent 
form, participants are contacted by phone for a nurse 
headache classification interview. People whose headache 
is confirmed to meet our entry criteria are then eligible 
for randomisation. If the nurse has a concern that the 
potential participant may have another headache type, 
there is a second interview with a doctor skilled in the 
management of headache disorders from the National 
Migraine Centre (http://www. nati onal migr aine centre. 
org. uk/). This is to ensure no one is inappropriately 
excluded and that people with a headache type needing 
more specific treatment are directed towards appropriate 
treatment. For example, 2/108 people in our feasibility 
study had cluster headaches.44 In such cases, we write to 
the GP and the participant with details on the excluded 
headache type and explain that they no longer fit the 
inclusion criteria for the CHESS trial.
Assignment of interventions
Randomisation
The randomisation is stratified by geographical locality 
(Midlands and Greater London) and headache type (six 
possible headache types: chronic tension type headache, 
probable chronic migraine and definite chronic migraine 
with or without MOH) using minimisation. Randomisa-
tion takes place using an online application specifically 
developed for the CHESS Study by the Warwick Clinical 
Trials Unit (WCTU) programming team.
Randomisation takes place when there are around 20 
participants who would be able to attend a local group if 
randomised to the active intervention. Typically these will 
come from 4 to 5 proximate general practices. However, 
people from other localities who are unable to attend a 
more local group and people who have self- referred to 
the study who are willing and able to travel to the sessions 
will also be included. By randomising in groups around 
2 weeks prior to the start of a group, we are able to mini-
mise any delay between randomisation and start of the 
intervention and ensure everyone has adequate follow- up 
from when they might have been exposed to the inter-
vention. For those that are subsequently unable to attend 
after randomisation to a group, we will offer them another 
group where possible.
Allocation concealment and protection from bias
Allocation concealment will be maintained by using 
Warwick CTU’s centralised randomisation service. All 
baseline data will be collected prior to randomisation. 
Blinding will be impossible for participants, facilitators 
and the central co- ordinating CHESS team. All data entry 
and checking is done blind to treatment allocation. The 
unbalanced randomisation means it is not possible blind 
the trial statistician to treatment allocation.
Our primary outcome is a participant completed 
outcome. Inevitably, participants will be aware of their 
treatment allocation. We will develop and sign off a 
detailed prespecified statistical analysis plan before allo-
cation codes are released.
data collection, management and analysis
Data collection methods
Data will be collected using two methods: postal survey 
questionnaires and a smartphone application (App) for 
headaches. All participants will be asked to complete a 
smartphone app about their headaches. If they do not 
have access to a smartphone or do not wish to use the 
app, a paper copy will be provided. Participants will 
initially complete the app weekly for up to 6 months to 
cover any period of withdrawal from medication, then 
monthly thereafter (still requiring them to reflect over the 
previous 7 days) until the end of the study at 12 months 
after randomisation. We are working with Clinvivo Ltd, 
a University of Warwick spin- out company specialising in 
electronic data collection, to capture data on headache 
frequency, duration and severity electronically using a 
smartphone app (table 3 shows the questions completed 
by participants and mode of response required). The 
data from the questions in the electronic diary will be 
numerical and downloaded into a WCTU database using 
a randomly generated 256- bit Advanced Encryption 
Standard (AES) key. At the end of the participants’ 12 
months, they will be provided with a summary report of 
their headache application data.
Reminders are sent to those participants who fail to 
downloaded the app or have not responded for more 
than 3 weeks. Reminders are sent by email or by post if 
there is no email address given.
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A daily detailed paper headache diary is kept only by 
the intervention arm participants, and the data will not 
be analysed by the study team but kept as a record by the 
participants and used during the one to one consultation 
where it will be collected and kept by the research team.
Data management
All questionnaire data received by the trial team are 
reviewed for completeness and entered onto a secure, 
backed- up bespoke database held at WCTU, which will 
be accessible only by authorised members of the team. 
Data from the smartphone app are downloaded securely 
(as described above) into the trial database. All data are 
checked when received, and any queries relating to the 
HIT6 CHQLQ or EQ5D are raised with the participant 
by telephone.
Statistical analysis of effectiveness and harms
Our primary endpoint analyses will be based on the 
12- month data.
Participants’ characteristics and reported outcomes will 
be summarised as means and SDs (for continuous data) 
or frequencies and percentages (for categorical data) 
by treatment arms. Difference between baseline and the 
three follow- up time points (4, 8 and 12 months post 
randomisation) will be computed for the primary and 
secondary outcomes by treatment arms.
The primary analysis approach will be intention to 
treat; that is, the data will be analysed according to the 
treatment the participant was originally allocated to, irre-
spective of what they actually received. We will explore 
the possibility of carrying out a complier averaged causal 
effect analysis as a sensitivity analysis. Our primary anal-
ysis will be the difference between the self- management 
therapy (intervention) and the relaxation therapy 
(control) groups with a 95% CI in the population with 
chronic migraine – if the proportion of participants with 
chronic tension type headache is ≤15%. The hypothesis 
testing of the primary outcome will be two sided at the 5% 
level, and the main analysis will estimate the treatment 
effect using a multilevel model to account for clustering 
(the model used to design this main trial). We will also 
present results for the whole population (all headache 
types). If the proportion of chronic tension type head-
ache is >15%, then the primary analysis will be according 
to the whole population of chronic headache (chronic 
migraine and tension type headache). Our experience is 
that NICE was specifically interested in data on specific 
headache types, excluding data that reported mixed 
population of people with chronic headaches. We will, 
therefore, in addition to our primary analyses, present 
the results (mean difference and 95% CI) for each of 
the two headache types with or without MOH separately 
and present results for those with or without medication 
overuse separately to facilitate future meta- analyses and 
inform future condition specific guidelines. All anal-
yses will be adjusted for the randomisation stratification 
factors (types of headache and geographical locality), 
sex, age and the baseline value of the dependent variable.
Similar analyses will be performed for all the other 
secondary outcomes. Prespecified subgroup analyses 
using formal statistical tests for interaction will examine 
whether baseline anxiety, depression and severity are 
moderators of treatment effect.46 We will assess the level 
of missingness in the primary outcome, and if required, 
we will use appropriate multiple imputation techniques 
to impute data and estimate the treatment effect as a 
form of sensitivity analysis. A full statistical analysis plan, 
including all primary and secondary analyses, will be 
written and signed off prior to releasing allocation codes 
to analysts and others involved in developing the plan.
Using the data from the smartphone app, we will 
generate a composite score for headache impact over the 
1 year of follow- up as the function of headaches days × 
average duration × average severity. Presenting these data 
graphically will allow any early benefits or harms from the 
intervention to be identified.
Health economic evaluation
Our economic evaluation will be conducted alongside 
the trial, and we will initially adopt a 1 year time horizon 
from both an NHS and personal social services perspec-
tive and, separately for the purpose of a sensitivity analysis 
a broader societal perspective, to estimate the cost- utility 
of the intervention. Resource use data will be collected to 
explore the costs of the delivery of the intervention and 
to estimate the key cost drivers. This will mainly consist 
of visits to the GP practice, medication usage and any 
adverse events (AEs) or length of stay in the hospital. In 
terms of costs to society, we will estimate time off work 
and any productivity losses associated with chronic head-
aches. Resource use information will be collected using 
self- completed postal questionnaires completed at 4, 8 
and 12 months after randomisation, as well as the use of 
routine health service data collected from general prac-
tice records. Resource input will be valued using national 
estimates of unit costs such as the Prescription Cost Anal-
ysis database or the Unit Costs of Health and Social Care 
compendium.47 Preference- based health- related quality 
of life outcomes will primarily be assessed through the 
completion of the EQ- 5D- 5L at each follow- up point.48 
Quality- adjusted life- years (QALYs) will be calculated as 
the area under the baseline- adjusted utility curve and will 
be calculated using linear interpolation between baseline 
and follow- up utility scores.
The results of the economic evaluation will be 
presented using incremental cost- effectiveness ratios, 
expressed in terms of incremental cost per QALY gained, 
and cost- effectiveness acceptability curves generated via 
non- parametric bootstrapping.
More extensive economic modelling using decision 
analytic methods will extend the target population, the 
time horizon to 5 years as the long- term natural history 
is unclear and the decision context, drawing on best 
available information from the literature together with 
 o
n
 April 14, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033520 on 12 April 2020. Downloaded from 
10 Patel S, et al. BMJ Open 2020;10:e033520. doi:10.1136/bmjopen-2019-033520
Open access 
stakeholder consultations to supplement the trial data. 
Longer term costs and consequences will be discounted 
to present values using nationally recommended discount 
rates recommended for health technology appraisal. We 
will use probabilistic sensitivity analysis to estimate the 
impact of uncertainty over model parameters. We will 
also use simple sensitivity analysis to assess the robust-
ness of the results to changes in deterministic parameters 
such as medication dosages, costs, discount rate and time 
horizon for patients presenting with chronic headaches. 
We will also explore cost- effectiveness of the intervention 
by conducting subgroup analyses for the different head-
ache types.
Monitoring, ethics and dissemination
Programme steering committee (PSC)
We have established a PSC to oversee the whole programme 
of work. The PSC functions specifically as a trial steering 
committee specifically for this trial. The PSC consists of 
seven members including two patient representative. The 
PSC will be responsible for oversight and monitoring and 
will consider any information from surveillance activity of 
other research in the field.
Data monitoring and ethics committee
A DMEC has been convened consisting of an independent 
statistician, a triallist, a clinician and a lay member. Confi-
dential reports that summarise the trial data and safety 
data will be reviewed by the Data Monitoring Committee 
(DMC). The DMC will advise the PSC as to whether to 
continue, amend or terminate the trial based primarily 
on safety and efficacy considerations
Harms/AEs
An AE or serious AE is any event that takes place on the 
way to, during or on the way home from the interven-
tion course. This includes the 2 days of the group course 
and the one- to- one nurse appointment. Our experience 
across multiple studies of group interventions is that AEs 
that are directly attributable to the intervention are rare.
Events during the session, such as severe psychological 
disturbance, any mild or moderate levels of emotional 
distress as a result of discussing experiences of living with 
chronic headache, a fall during travel to and from the 
venue or any other AEs, occurring during the delivery of 
the intervention will be reported to the trial co- coordi-
nator by the intervention team. Any short- term increase 
in headaches as a consequence of medication withdrawal 
will be captured using the smartphone app (or paper 
version for those without access to a smartphone).
All AEs will be managed in line with Warwick CTU’s 
standard operating procedures.
Process evaluation
A separate mixed- methods process evaluation is running 
alongside the trial. This will explore both the process of 
implementation the trial and the process of delivering 
and receiving the intervention. The process evaluation 
protocol is reported elsewhere.49
The fidelity of the delivery of the intervention will 
be assessed by this team in three ways, through: audio 
recording of the groups, facilitator reflection and partic-
ipant feedback. This will assess facilitator competence, 
adherence to the course manual and trial procedures and 
participant interaction and engagement.
Patient and public involvement
We have had substantial PPI in the feasibility study prior 
to finalising this protocol. Lay members were involved in 
the development of the classification interview, develop-
ment of the intervention, PROM selection and conduct 
and management of the study via the independent 
programme steering and trial management group.
Our trial management group includes our lay coap-
plicants who are representatives of three leading UK 
migraine charities (The Migraine Trust, Migraine Action 
(before their merger with Migraine Trust) and National 
Migraine Centre).
We have developed a lay steering group who are and 
will be collaboratively involved during the study. At key 
points in the programme we will approach the lay steering 
group for input, this will include at the end of the trial 
when results are disseminated.
EthICs And dIssEMInAtIon
The University of Warwick (Research Impact Services, 
University of Warwick, Coventry CV4 7AL) is the sponsor 
for the study.
The trial is conducted in accordance with the principles 
outlined in the Declaration of Helsinki and conforms to 
Good Clinical Practice (GCP) and Standard Operating 
Procedures (SOPs) set- out by the WCTU. As reported 
above, we have convened a PSC and DMC to oversee the 
trial.
All identifiable data are anonymised and treated as 
confidential. Participants are informed that they are free 
to withdraw at any time during any phase of the work.
The findings from this trial will be disseminated via a 
final report to the National Institute for Health Research 
(NIHR), presentations at conferences and publications in 
high- quality peer- reviewed journals.
For the healthcare professionals involved in the study, 
we will disseminate results of the study through the study 
website. We will also host a meeting to present the trial 
results to commissioners and clinicians. For the partici-
pants, we will provide a written lay summary of the find-
ings and also publish these on a study specific website, 
with contact information should they wish to discuss the 
findings. Our charity partners will be involved with feed-
back to the organisations they represent.
ConClusIon
At the time of writing (8 August 2019), a total of 736 
participants have been randomised (380 to the interven-
tion arm and 356 to the control arm), and the trial is now 
in the follow- up phase.
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A comprehensive programme of preparatory work has 
allowed this substantial trial of an education and self- 
management intervention for people living with chronic 
headaches to be developed. There is a clear interest in 
taking part in the trial. Our follow- up will be complete in 
early 2020, and the final results will be published in 2021.
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